P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12010852.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic bronchitis is in part characterized by mucus hypersecretion and the inability to clear airways of mucus. Despite years of research in this area, to date there are no pharmacologic therapies available to enhance or promote mucociliary clearance. P2Y(2) receptor agonists are a new class of mucoactive compounds that are currently under development for this purpose. This article will review the pharmacology of P2Y(2) receptor agonists, review the clinical studies performed to date, and highlight the challenges inherent in the development of therapies with these pharmacologic properties.
Medical subject headings
- Anti-Asthmatic Agents
- Bronchitis, Chronic
- Mucociliary Clearance
- Polyphosphates
- Purinergic P2 Receptor Agonists
- Uracil Nucleotides